IL-17-targeted monoclonal antibodies (iMab)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameIL-17-targeted monoclonal antibodies (iMab)
Drug Alias Nameanti-IL-17 mAbs (iMab)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionInterleukin-17 inhibitors
TargetsInterleukin-17
Therapy Area/IndicationsAutoimmune Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryRussian Federation
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesiMAb Llc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesiMAb Llc
Active IndicationsN/A
Inactive IndicationsAutoimmune Diseases

Other Information

ATC CodeN/A
Related LinksN/A